Danish pharma large Novo Nordisk teased promising early-phase trial effects of its experimental weight loss capsule amycretin, sending the corporation’s stock surging.GLP-one agonist medications, normally referred to as GLP-1s, are injectable remedies that work by mimicking the GLP-one hormone that your smaller intestine tends to make in reaction